Advertisement
OtherDRUG METABOLISM AND DISPOSITION

Kinetic Study of the Hepatobiliary Transport of a New Prostaglandin Receptor Agonist

Haruo Imawaka and Yuichi Sugiyama
Journal of Pharmacology and Experimental Therapeutics March 1998, 284 (3) 949-957;

Abstract

The pharmacokinetics of the hepatobiliary transport of an anionic drug, 7,8-dihydro-5-[(E)-[[a-(3-pyridyl)-benzylidene]aminooxy]ethyl]-1-naphthyloxy]acetic acid (ONO-1301), a new prostaglandin (PG) I2 receptor agonist, was investigated in rats. During intravenous infusion of this compound, the drug concentrations in arterial blood, hepatic vein and liver and the biliary excretion rate were measured at steady state. At a low infusion rate, 30% of the ONO-1301 was extracted by the liver during a single pass, and the main clearance organ was demonstrated to be the liver. The total clearance, Cltot; hepatic extraction ratio, EH; and liver-to-plasma concentration ratio, Kp values, decreased as the infusion rate increased. Considering the infusion rate-dependent decrease in all three parameters, saturation of hepatic uptake was suggested to be the cause of the nonlinear pharmacokinetics. To confirm this hypothesis, the time profiles of the plasma and liver concentrations of ONO-1301 after intravenous administration of various doses (0.01–25 mg/kg) were analyzed in vivo. The early-phase hepatic uptake clearance at lower doses (0.01–1 mg/kg) was 28 ml/min/kg, which is close to the hepatic plasma flow rate. The uptake clearance also was decreased at the higher doses. The uptake mechanism was investigated with isolated rat hepatocytes. Both Na+-dependent and -independent uptake were observed and these were inhibited by hypothermia and ATP depletors, which suggests that the uptake is via carrier-mediated active transport. The initial uptake velocity exhibited concentration dependence, and the kinetic parameters were as follows:Km, 15.6 μM (Na+-dependent) and 3.8 μM (Na+-independent);Vmax, 5.9 nmol/min/mg (Na+-dependent) and 4.8 nmol/min/mg (Na+-independent). With these in vitrotransport parameters, the plasma unbound fraction and the hepatic plasma flow rate, the hepatic uptake clearance was calculated from a mathematical model. The calculation also indicated that the uptake was so rapid that it was limited by the plasma flow rate. It is concluded that the carrier-mediated active transport systems demonstratedin vitro are responsible for the nonlinear pharmacokinetics of ONO-1301.

During research to develop an orally active and long-lasting PGI2 analog, a novel compound, ONO-1301, was found. Although this compound possesses a nonprostanoid structure, it exhibits potent PGI2 activity and inhibits thromboxane A2 in vitro and in vivo (Kondo et al., 1995).

Besides renal excretion, hepatic metabolism and biliary excretion are the major pathways involved in the removal of xenobiotics. Our quantitative studies have demonstrated that hepatic uptake is the rate-limiting step in the hepatic clearance of several drugs (Miyauchiet al., 1987, 1993). In this case, saturation of membrane transport is one of the factors that causes the nonlinearity of hepatic clearance (Yamazaki et al., 1996). In addition, it has been reported that carrier-mediated transport contributes to hepatic uptake and/or biliary excretion (Petzinger 1994; Elferink et al., 1995). As far as the hepatic uptake is concerned, it is well established that hepatic uptake of the conjugated bile acid, taurocholate, is mediated predominantly by a secondary active transport process driven by an out-to-in Na+ gradient (Anwer and Hegner, 1978; Inoue et al., 1982; Yamazakiet al., 1993b). The Na+-taurocholate cotransporting different proteins (Ntcp and epoxide hydrolase) have been characterized and cloned by two groups (Hagenbuch et al., 1991, 1994; von Dippe et al., 1996), and it has been reported that the hepatic uptake of various organic anions such as DBSP, pravastatin and leukotriene C4 is mediated by a oatp, which also has been cloned (Jacquemin et al., 1991, 1994; Kullak-Ublick et al., 1995). In addition, the cDNA sequence of a specific PGT has been reported, and the presence of this transporter has been demonstrated in liver as well as other tissues (lung, kidney, etc.); it exhibits similarities to oatp in terms of amino acid sequence and substrate specificity (Kanai et al., 1995).

Regarding biliary excretion, a primary active transport system for several compounds which is coupled directly to ATP-hydrolysis has been reported (Ishikawa et al., 1990; Kobayashi et al., 1990). The existence of transporters for conjugated bile acids, organic anions (canalicular Multispecific Organic Anion Transporter) and amphipathic organic cations including anticancer drugs (P-gp) was demonstrated (Elferink et al., 1995; Ishikawaet al., 1990; Ito et al.,1996; Meijer et al.; 1990; Mayer et al., 1995).

ONO-1301 is an organic anion with a carboxyl group (fig.1) and is an agonist specifically bound to the PG receptor; therefore, hepatic uptake and biliary excretion may be mediated by the transporters described above. In this study, we carried out a kinetic investigation of the hepatobiliary transport of ONO-1301 and its mechanism of hepatic uptake.

Figure 1
Figure 1

Chemical structure of ONO-1301.

Materials and Methods

Materials

[14C]ONO-1301 (1.10 GBq/mmol) and unlabeled ONO-1301 were donated by ONO Pharmaceutical Co. Ltd. (Osaka, Japan). Rotenone was purchased from Sigma Chemical Co. (St. Louis, MO). FCCP was purchased from Aldrich Chemical Co. (Milwaukee, WI). All other chemicals were of reagent grade.

Animals

Male Sprague-Dawley rats (250–300 g, Nihon Ikagaku Doubutsu Shizai Kenkyusyo, Tokyo, Japan) were used.

In Vivo Infusion Study

Under ether anesthesia, the femoral vein and artery were cannulated with PE-50 polyethylene tubing for ONO-1301 administration and blood sampling, respectively. The bile duct was cannulated with PE-10 polyethylene tubing and the hepatic vein also was cannulated by the method of Yokota et al. (1976). ONO-1301 dissolved in physiological saline was infused through the femoral vein cannula at a flow rate of 0.8, 8 or 80 mg/kg/hr for 30 min after the beginning of the infusion and then at a flow rate of 0.2, 2 and 20 mg/kg/hr. The concentration of ONO-1301 solutions were 0.2, 2 and 20 mg/ml, respectively. After a certain interval, arterial blood and bile samples were collected in polyethylene tubes. To obtain plasma, blood was centrifuged at 10,000 × g for 2 min in a tabletop microcentrifuge (Microfuge E, Beckman Instruments, Inc., Fullerton, CA). The concentration of ONO-1301 was determined by HPLC. HPLC analysis was performed on a CAPCELLPAK C18 UG-120 column (S-5 μm, 150 mm × 6 mm inside diameter [i.d.]). The mobile phase consisted of CH3CN/0.02 M phosphate buffer (pH 9.0) (1:4) (solvent A) and CH3CN/0.02 M phosphate buffer (pH 9.0) (2:3) (solvent B). A linear gradient was run from 0 to 25 min to increase solvent B from 45% to 100%, followed by a 15 min elution with 100% solvent B; a reverse gradient reduced the solvent B content back to 55% at 40 min. The flow rate was 1.0 ml/min, and the column effluent was monitored at 265 nm. AP-501–01 (0.2 μg; the isomer of ONO-1301) was added to plasma or bile specimens as an internal standard. Plasma and bile specimens (5–100 μl) were mixed with 1 ml ethanol, the mixture was stirred with the vortex mixer and centrifuged at 3,000 rpm for 10 min. The supernatants were evaporated to dryness, and the samples were redissolved in HPLC mobile phase. The liver (0.1 mg) was homogenized with 1 ml ethanol and centrifuged at 3,000 rpm for 10 min. A selected volume (30–100 μl) of supernatant was mixed with internal standard solution and evaporated to dryness, and the sample was redissolved in HPLC mobile phase. Quantitation of ONO-1301 in plasma, bile and liver was accomplished with calibration curves obtained by plotting the ratio of the appropriate peak area to the internal standard (ONO-AP-501–01). Linearity was observed for concentrations of 0.1 to 1 μg/tube. The straight-line equation was y = 1.32x − 0.00050 [y = peak area ratio, ONO-1301/IS;x = amount of ONO-1301 (μg) per tube]. The correlation coefficient, r, was 0.999. Precision and accuracy of the assay were determined for three injections per concentration, and seven concentrations. The precision was less than 14.3%, and the accuracy was less than 6.7%. Typical HPLC chromatograms of biological samples (plasma, bile and liver) are shown in figure 2.

Figure 2
Figure 2

Typical HPLC chromatograms of biological samples. (A) Plasma sample 60 min after the beginning of the infusion; (B) bile sample from 55 min to 65 min after the beginning of the infusion; (C) liver sample 65 min after the beginning of the infusion. No metabolite peaks occurred in plasma and liver, but as far as the bile samples were concerned, some peaks were considered to be caused by metabolites.

Total body clearance (CLtot) was calculated from the following equation:CLtot=I/Ca,ss Equation 1where, I represents the infusion rate of ONO-1301,Ca,ss is the arterial plasma concentration of ONO-1301 60 min after the beginning of the infusion.

Hepatic extraction ratio (EH) was calculated from the following equation:EH=(Ca,ss−Chv,ss)/Ca,ss Equation 2where, Chv,ss is the hepatic venous plasma concentration of ONO-1301 65 min after the beginning of the infusion.

The liver-to-plasma concentration ratio (Kpvalue) was calculated from the following equation:Kp=Cliver/Chv,ss Equation 3where, Cliver is the liver concentration of ONO-1301 65 min after the beginning of the infusion.

Biliary excretion clearances based on plasma and liver concentrations of ONO-1301 (CLbile,plasma and CLbile,liver) were determined as follows:CLbile,plasma=Vbile/Chv,ss Equation 4CLbile,liver=Vbile/Cliver Equation 5where Vbile is the biliary excretion rate of ONO-1301.

Binding of ONO-1301 to Serum or Liver Cytosolic Protein

The equilibrium dialysis method was used to determine the extent of binding of [14C]ONO-1301. Two-chamber dialysis cells divided by a dialysis membrane (Visking sheet, Sanplatec, Osaka, Japan) were used. A volume of 400 μl serum or 33% (w/v) cytosol was put in to one chamber, and the same volume of phosphate buffer (pH 7.4) was put in to the other. ONO-1301 was added to the serum or cytosol side to produce specified concentrations of ONO-1301 (3–1000 μM). The chambers were then incubated at 37°C for 6 hr (serum) or 4°C for 48 hr (cytosol), long enough to reach equilibrium. The concentration of ONO-1301 in both serum or cytosol and buffer sides was then measured. The binding to cytosol was determined at a low temperature to minimize the denaturation of binding protein(s).

The experimental data were fitted to the following equation to determine the binding parameters to serum and liver cytosol, respectively:Cb=n(P)t·CfKd+Cf Equation 6Cb=n(P)t·CfKd+Cf+α·Cf Equation 7where Cb,Cf,n(P)t,Kd and α are the ligand concentration bound to protein(s), unbound concentration of ligand, binding capacity, dissociation constant and proportionality constant for nonspecific binding, respectively. Assuming that both the binding affinity and the binding capacity per unit protein are unaffected by the dilution of cytosol, the binding to physiological undiluted cytosol was calculated by use of three times the binding capacity [n(P)t] obtained from binding studies which were carried out with 33% diluted cytosol.

Identification of the binding protein in the cytosol

Gel filtration was used to identify the protein responsible for binding ONO-1301. The cytosol specimen was prepared as follows: liver homogenates (33% w/v) in 50 mM potassium phosphate buffer (pH 7.4) were prepared from three rats and then pooled to give 100,000 ×g cytosol fractions (Tsao et al., 1988; Chunget al., 1990; Sathirakul et al., 1993). ONO-1301 (final concentrations of 10 μM) was added to an aliquot of the cytosolic specimen (0.5 ml). After 15 min incubation at 37°C, 0.2 ml of the mixture was analyzed by HPLC with a gel filtration column (Asahipak GS-510, 50 cm × 7.6 mm i.d., Asahikasei Kogyo Co., Ltd., Kawasaki, Japan). The solvent system used was 50 mM potassium phosphate buffer (pH 7.4) at a flow rate of 0.5 ml/min and fractions (0.5 ml) were collected.

The protein concentration was measured spectrophotometrically at 280 nm, and the radioactivity of [14C]ONO-1301 was determined in a liquid scintillation spectrophotometer (LS 6000SE, Beckman Instruments, Inc., Fullerton, CA). GST activity in the eluted fractions of liver cytosol obtained by HPLC was measured as reported elsewhere (Sugiyama et al., 1981). The GST activity with respect to 1-chloro-2,4-dinitrobenzene was determined by monitoring changes in the absorbance at 340 nm. The GST activity is expressed as the formation of products per min per fraction.

Measurement of Hepatic Blood Flow

Under ether anesthesia, the femoral vein was cannulated with PE-50 polyethylene tubing for ONO-1301 administration. All doses of ONO-1301 (0.2, 2 and 20 mg/kg/hr) were dissolved in saline and infused through the femoral vein. The abdomen was opened by a downward midline incision extending about 8 cm from the diaphragm. The central lobe of the liver was deflected to the upper left with a gauze soaked in saline. The hepatic artery and portal vein were separated gently, and any fat was removed. The probe was placed around the portal vein and hepatic artery, the central lobe was returned to its normal position and then the abdomen was closed. The hepatic blood flow was measured at steady state before and after the beginning of drug infusion (small animal blood-flow meter, T106, Transonic Systems Inc. Ithaca, NY).

Initial Uptake Clearance in Vivo (Integration Plot Analysis)

Under ether anesthesia, the femoral vein and artery were cannulated with PE-50 polyethylene tubing for ONO-1301 administration and blood sampling, respectively. All doses of ONO-1301 (25.7 kBq, 0.01–25 mg/kg) were dissolved in saline and administered through the femoral vein, and blood samples were collected at certain intervals. At 2 to 5 min, rats were sacrificed, the liver excised and a portion of the tissue weighed and counted for radioactivity. When a tracer dose of ONO-1301 is given intravenously and liver uptake measured within a short period during which efflux and biliary excretion of the parent drug and metabolite from the liver is negligible, the liver uptake rate of ONO-1301 can be described by the following differential equation:dXt/dt=CLuptake,in vivo·Cp Equation 8where Xt is the amount of ONO-1301 in the liver at time t, CLuptake,in vivo is the uptake clearance and Cp is the plasma concentration of ONO-1301 at time t. TheCp values were determined by measuring total radioactivity because thin-layer chromatography analysis indicated that >90% of the total radioactivity in the plasma came from unchanged [14C]ONO-1301. Integration of equation 8 gives:Xt=CLuptake,in vivo·AUC(0­t) Equation 9where AUC(0–t) represents the area under the plasma concentration-time curve from time 0 tot. Equation 9 divided by CpgivesXt/Cp=CLuptake,in vivo·AUC(0­t)/Cp Equation 10

The CLuptake,in vivo value can now be obtained from the initial slope of a plot ofXt/Cpvs. AUC(0–t)/Cp, designated as the “integration plot” (Kim et al., 1988;Yanai et al., 1990).

Isolated Rat Hepatocytes

Cell preparation.

Hepatocytes were isolated from male SD rats (250–300 g) by a two-step collagenase perfusion method modified from the procedure of Baur et al. (1975). The liver was perfused at 37°C for 20 min with the following medium: 137 mM NaCl, 5.4 mM KCl, 0.5 mM NaH2PO4, 0.42 mM Na2HPO4, 10 mM HEPES, 4.2 mM NaHCO3, 0.5 mM EGTA, 5 mM glucose, equilibrated with 95% O2-5% CO2. Collagenase (from Clostridium histoliticum hepatocyte isolation grade; Wako Pure Chemical Industries, Ltd., Osaka, Japan), trypsin inhibitor (Type I-S, from Soybean; Sigma Chemical Co., St. Louis, MO) and calcium ion were added to 100 ml EGTA and glucose-free perfusate to give a final concentration of 0.05%, 0.005% and 5 mM, respectively. The liver was then perfused with the collagenase solution for an additional 15 min. After isolation, hepatocytes were suspended (1 mg protein/ml) at 0°C in albumin-free Krebs-Henseleit buffer supplemented with 12.5 mM HEPES (pH 7.3). Cell viability was checked routinely by the trypan blue [0.38% (w/v)] exclusion test. Viability ranged from 85% to 95%.

Uptake study.

Uptake of [14C]ONO-1301 (0.5 μM) was initiated by adding ligand to the preincubated (37°C for 3 min) cell suspension (1 mg protein/ml). At designated times, the reaction was terminated by separating the cells from the medium by centrifugal filtration (Schwenk, 1980). Aliquots (200 μl) were placed into 0.4 ml centrifuge tubes containing 50 μl 2 N NaOH, covered by 100 μl of a mixture of silicone and mineral oil (density, 1.015). The samples were then centrifuged for 15 s in a tabletop microfuge (Beckman Instruments, Fullerton, CA). Centrifugation drove the hepatocytes through the oil layer into the 2 N NaOH solution. After the cells dissolved in the alkaline solution, the tube was sliced with a razor blade, and both compartments [medium and bottom compartments (including the cells)] were transferred to scintillation vials. The bottom contents were neutralized with 50 μl 2 N HCl. Then 5 ml of counting solution was added to the vial, and both cell and medium radioactivity was determined in a liquid scintillation spectrophotometer (LS 6000SE, Beckman Instruments, Inc., Fullerton, CA). The time course of ONO-1301 uptake was plotted in terms of the cell-to-medium concentration ratio (C/M ratio), so that one could monitor the extent to which the ligand had been concentrated in the cell. Initial uptake velocity was calculated by linear regression of points taken at 20 and 60 s. To estimate Na+-independent ONO-1301 uptake, the uptake study was performed in the absence of external Na+. Under these experimental conditions, choline was used in the incubation buffer. The composition of the choline buffer was the same as the Krebs-Henseleit buffer except that the NaCl and NaHCO3 were replaced with isotonic choline chloride and choline bicarbonate, respectively. Na+-dependent ONO-1301 uptake was calculated by subtracting the uptake with choline buffer from the total uptake measured with Krebs-Henseleit buffer containing Na+ (142 mM).

Determination of Kinetic Parameters

The kinetic parameters for ONO-1301 uptake were estimated from the following equation:V0=Vmax·SKm+S+Pdif·S Equation 11

where V0 is the initial uptake rate of ONO-1301 (pmol/min/mg), S is the ONO-1301 concentration in the medium (μM), Km is the Michaelis constant (μM), Vmax is the maximum uptake rate (pmol/min/mg) and Pdif is the nonspecific uptake clearance (μl/min/mg). This equation was fitted to the uptake data sets by an iterative nonlinear least-squares method with a MULTI program (Yamaoka et al., 1981) to obtain estimates of the kinetic parameters. The input data were weighted as the reciprocal of the square of the observed values, and the algorithm used for the fitting was the Damping Gauss Newton Method (Yamaokaet al., 1981).

Estimation of Hepatic Uptake CL from the in Vitro Data

Based on the kinetic parameters obtained by the fitting procedure described, under linear condition, the permeability-surface area product, PSinflux,in vitro (ml/min/kg rat) was calculated from the following equation:V0S=PSinflux,in vitro=[(Vmax/Km)+Pdif]·(α/β)·γ Equation 12where α = 1.25 × 108 (cells/g of liver, Lin et al., 1980), β = 1.0 × 106 (cells/mg protein) and γ = 44 (g liver/kg rat, Sugita et al., 1982).

The in vivo uptake CL (CLuptake,in vivo, ml/min/kg rat) was then estimated from the in vitro PSinflux,in vitro with the dispersion model (equation 13) (Roberts and Rowland, 1986):CLuptake,in vivo  Equation 13=QB·1−4a(1+a)2·exp{(a−1)/2DN}−(1−a)2·exp{−(a+1)/2DN} where,a=(1+4 RN·DN)1/2 Equation 14RN=fu·PSinflux,in vitroQB·RB Equation 15DN is the dispersion number,QB is the hepatic blood flow rate in rats,fu is the unbound fraction of ONO-1301 andRB is the blood-to-plasma concentration ratio. In the analysis with the dispersion model, aDN of 0.17 was used (Iwatsubo et al., 1996).

Results

In vivo infusion study.

After intravenous infusion (0.2, 2 and 2 mg/kg/hr), the plasma concentrations in both arterial and hepatic venous blood, the liver concentration and the biliary excretion rate of ONO-1301 were measured at steady-state. CLtot, EH andKp were calculated from equations 1, 2 and3, respectively. These results are shown in table1. All parameters remained constant at 50 and 60 min after the beginning of the intravenous infusion, 0.2 to 20 mg/kg/hr, having reached steady state. TheEH value was estimated to be 0.31 for the 0.2 mg/min/kg infusion, which indicates that 30% of ONO-1301 molecules were extracted by the liver during a single pass. CLH was estimated to be 12.2 to 6.7 ml/min/kg at 0.2 to 2 mg/min/kg and was similar to CLtot(6.5–5.7 ml/min/kg), so the main clearance organ was suggested to be the liver. The CLtot,EH and Kpvalues in the liver decreased as the infusion rate increased (table 1). The biliary excretion rates of ONO-1301 normalized for the infusion rate (Vbile/I) at steady state at 0.2, 2 and 20 mg/kg/hr were 9.15 ± 0.71%, 10.6 ± 1.1% and 4.96 ± 0.89%, respectively. The biliary excretion clearance based on the plasma concentration of ONO-1301 (CLbile,plasma) decreased as the infusion rate increased; on the other hand, the clearance rates based on the liver concentration (CLbile,liver) increased (table 1).

View this table:
Table 1

Dose dependence of the kinetic parameters for ONO-1301 at steady state (60 min after the beginning of the intravenous infusion)1-a

Binding to serum protein.

The binding of ONO-1301 to serum protein was studied by equilibrium dialysis; distribution of ONO-1301 to blood cells also was studied. ONO-1301 distribution in blood cells was negligible. The Scatchard plot for the binding of ONO-1301 to rat serum protein (fig. 3) revealed the presence of a single kind of binding site. The binding capacity [n(P)t] and dissociation constant (Kd) were estimated to be 1860 μM and 38.2 μM, respectively. Then(P)t value was approximately four times the serum albumin concentration (0.4–0.6 mM), which suggests the existence of four binding sites on an albumin molecule. The free fraction remained constant (1.81 ± 0.03%) from 3 to 50 μM, but was increased at concentrations >100 μM. The free fraction was estimated to be 2.62 ± 0.13% at a concentration of 400 μM, corresponding to the plasma concentration of ONO-1301 in the in vivo study with the highest infusion rate (20 mg/kg/hr), and was 4.17 ± 0.19% at 1 mM.

Figure 3
Figure 3

Scatchard plot for serum protein binding of ONO-1301. ONO-1301 was added to the serum side of the dialysis cell to produce final concentrations of 3 to 1000 μM. The dialysis cells were then incubated at 37°C for 6 hr. Cb andCf represent the concentration bound to serum protein and the unbound concentration of ONO-1301, respectively. Each symbol and vertical bar represents the mean ± S.E. of three data points. The solid line represents the fitted line (equation 6).

Binding to cytosolic protein.

The distribution of ONO-1301 between cytosol and other organelles was measured. The ratio of the amount in the cytosol to the total amount in homogenate was 23%. The binding of ONO-1301 to 33% cytosol was quantitated by equilibrium dialysis. Figure 4 shows the Scatchard plot for the binding of ONO-1301 to cytosolic protein. The binding data were fitted to equation 7. For the binding of ONO-1301, saturable and nonsaturable components were observed. TheKd value was 5.4 μM. Then(P)t value of ONO-1301 in 100% cytosol was estimated to be 117 μM by extrapolating the binding data obtained in diluted cytosol specimens (33% cytosol). The free fraction remained constant (2.50–2.86%) from 3 to 20 μM, but was increased at concentrations >50 μM. The free fraction was estimated to be 4.95 ± 0.60% at a concentration of 600 μM, corresponding to the liver concentration of ONO-1301 in the in vivo study with the highest infusion rate (20 mg/kg/hr).

Figure 4
Figure 4

Scatchard plot for cytosol protein binding of ONO-1301. ONO-1301 was added to the cytosol side of the dialysis cell to produce final concentrations of 3 to 1000 μM. The dialysis cells were then incubated at 4°C for 48 hr. Cband Cf represent the concentration bound to cytosol protein and the unbound concentration of ONO-1301, respectively. Each symbol and vertical bar represents the mean ± S.E. of three data points. The solid line represents the fitted line (equation 7).

Identification of binding protein in the cytosol.

The binding of ONO-1301 to cytosolic protein was studied by gel filtration. The elution pattern for the protein and associated radioactivity is shown in figure 5. The determination of the GST activity in the eluent fraction suggested that the peak of GST activity coincided with that of the radioactivity, and the protein responsible for binding ONO-1301 in liver cytosol may be ligandin (Sugiyamaet al., 1983; Takenaka et al., 1995).

Figure 5
Figure 5

Elution pattern for the binding of ONO-1301 to the liver cytosol of rats. [14C]ONO-1301 was added to 0.5 ml of liver cytosol to produce final concentrations of 10 μM. Specimens were incubated at 37°C for 15 min and then applied to HPLC with a gel filtration column (Asahipak GS-510, 50 cm × 7.6 mm i.d.). The solvent system used was 50 mM potassium phosphate buffer (pH 7.4) at a flow rate of 0.5 ml/min. See details in the text. Solid line, protein absorbance (UV 280 nm), ○; radioactivity of [14C]ONO-1301, 152 ; GST activity.

Measurement of hepatic blood flow.

The effect of a constant infusion of ONO-1301 (0.2, 2 and 20 mg/kg/hr) on the hepatic blood flow rate was measured. Before beginning the infusion, the hepatic blood flow rate was 59.1 ml/min/kg. The hepatic blood flow rate was not affected by the infusion of saline but was increased by ONO-1301 in a dose-dependent manner. The hepatic blood flow rate increase reached almost constant (by 30%) at the infusion rate of 2 mg/kg/hr (table2).

View this table:
Table 2

Hepatic blood flow rates

Initial uptake clearance in vivo (integration plot analysis).

To investigate directly the saturation of hepatic uptake, the time profiles of plasma and liver concentrations of ONO-1301 after intravenous administration of various doses (0.01–25 mg/kg) were analyzed in vivo (fig.6). The early-phase hepatic uptake clearance (CLuptake,in vivo) over the linear range (0.01–1 mg/kg) was 27 to 30 ml/min/kg, which is close to the hepatic plasma flow rate. CLuptake,in vivo decreased as the dose increased and fell to 14.3 ml/min/kg at a dose of 25 mg/kg (fig. 7).

Figure 6
Figure 6

Dose-dependent change in the “integration plot” for the hepatic uptake of ONO-1301 after intravenous administration to rats. After intravenous administration of [14C]ONO-1301 (•, 0.01 mg/kg; ▵, 5 mg/kg; □, 25 mg/kg), both plasma concentration (Cp) time profiles and uptake by the liver were measured and the data expressed as an integration plot (equation 11). The slope represents CLuptake,in vivo.

Figure 7
Figure 7

Dose dependence of ONO-1301 uptake clearances (CLuptake,in vivo). ONO-1301 was administered at 0.01, 0.2, 1, 5, 10 and 25 mg/kg, and CLuptake,in vivo was estimated by integration plot analysis as shown in figure 6.

Isolated rat hepatocytes.

[14C]ONO-1301 uptake by isolated rat hepatocytes increased in a time-dependent manner and a highly concentrative uptake was observed, e.g., the cell-to-medium (C/M) concentration ratio at 5 min was 8000. ONO-1301 exhibited both Na+-dependent and -independent uptake (fig.8). The initial uptake velocity exhibited a concentration dependence, and the Eadie-Hofstee plot of the uptake data is shown in figure 9. The kinetic parameters were as follows: Na+-dependent parameters; Km = 15.6 ± 5.4 μM,Vmax = 5.9 ± 1.6 nmol/min/mg,Pdif = 12.9 ± 5.4 μl/min/mg (mean ± computer-calculated S.D.), Na+-independent parameters;Km = 3.8 ± 0.8 μM,Vmax = 4.8 ± 0.6 nmol/min/mg,Pdif = 29.3 ± 4.8 μl/min/mg (mean ± computer-calculated S.D.).

Figure 8
Figure 8

Time course of ONO-1301 uptake by isolated rat hepatocytes. Uptake of [14C]ONO-1301 was measured by incubating the isolated rat hepatocytes in Krebs-Henseleit buffer (pH 7.3) containing 0.5 μM [14C]ONO-1301 in the presence (□) and absence (▪) of Na+ at 37°C after preincubation for 3 min. Na+-dependent ONO-1301 uptake (○) was calculated by subtracting the uptake with choline buffer from the total uptake measured. The uptake value (C/M ratio) means the cellular uptake amount divided by the extracellular concentration. Each symbol and vertical bar represents the mean ± S.E. of nine determinations in three different preparations.

Figure 9
Figure 9

Eadie-Hofstee plot of ONO-1301 uptake by isolated rat hepatocytes. Uptake of ONO-1301 was measured at concentrations of 0.2, 0.5, 1, 2, 5, 10, 20, 100 and 500 μM in the absence (Na+-independent uptake, (○) and presence of Na+. Na+-dependent ONO-1301 uptake (•) was calculated by subtracting the uptake with choline buffer from the total uptake measured. Solid (Na+-independent uptake) and dotted (Na+-dependent uptake) lines represent the fitted line.

Furthermore, the uptake of ONO-1301 was inhibited in the presence of an ATP depletor, such as rotenone (30 μM) and FCCP (2 μM), and was markedly inhibited also by hypothermia (table3). The effect of the mutual inhibition of ONO-1301 uptake by TCA or pravastatin (Yamazaki et al., 1993a), which are typical substrates of Na+/TCA cotransporter and the oatp, respectively, was examined. TCA and pravastatin inhibited the uptake of ONO-1301 both in the presence and absence of external Na+ in a concentration-dependent manner; however, their inhibitions were only partial (table 3). That is, the highest concentration (500 μM) of TCA and pravastatin, which is more than 10 times theKm values for their own uptake, inhibited the ONO-1301 uptake only by 50%. The half-inhibition concentrations of TCA and pravastatin for the inhibitable ONO-1301 uptake were approximately 20 μM and 50 μM, respectively (table 3). On the other hand, ONO-1301 inhibited the uptake of TCA and pravastatin almost completely, and the half-inhibition concentration of ONO-1301 was approximately 10 μM (table 3).

View this table:
Table 3

Effects of various inhibitors and hypothermia on uptake of ONO-1301, and effects of ONO-1301 on the uptake of TCA and pravastatin by isolated rat hepatocytes3-a

Estimation of hepatic uptake clearance from the in vitro uptake data.

Based on the kinetic parameters obtained from in vitro experiments, the PSinflux,invitro was calculated from equation 12 as 9400 ml/min/kg. Considering that the free fraction of ONO-1301 was 0.018,fu · PSinflux,in vitro was calculated as 171 ml/min/kg. This value was five times that of the hepatic plasma flow rate (32.5 ml/min/kg), which is the product of the hepatic blood flow rate (59.1 ml/min/kg) and the hematocrit (0.45), which suggests that the hepatic uptake is blood-flow rate-limited. Actually, the CLuptake,in vivo estimated from equations 13 to 15 was 31.5 ml/min/kg, which is close to the hepatic plasma flow rate and agrees with the value (29 ml/min/kg) obtained from the in vivo study at a dose of .01 mg/kg (fig. 7).

Discussion

The hepatobiliary transport of ONO-1301 was analyzed kinetically in rats in vivo. During intravenous infusion of this compound, CLtot at steady state decreased as the infusion rate increased and exhibited nonlinearity (table 1). After a single intravenous administration of [14C]ONO-1301, most of the total radioactivity from the injected dose was recovered in the bile (H. Imawaka, unpublished data). These results suggest that hepatic uptake, hepatic metabolism and biliary excretion may be important factors governing the disposition of this drug.

Both CLtot and EHdecreased as the infusion rate increased. At 2 mg/kg/hr infusion, CLtot decreased to only approximately 90% of the CLtot at 0.2 mg/kg/hr, whereas the decrease inEH was approximately 50%. The decrease was more marked for EH than CLtot at 20 mg/kg/hr (8% and 30% of that at 0.2 mg/kg/hr, respectively) (table 1). This phenomenon may be caused by an increase in hepatic blood flow rate with ONO-1301 administration. Therefore, to investigate the effect of ONO-1301 on the hepatic blood flow rate, QB was measured directly with a blood flow meter under ether anesthesia. Ether anesthesia affects both blood flow as well as drug metabolism (Watkins and Klaassen, 1983). It is doubtful whether the blood flow rate observed in this experiment is the physiological hepatic blood flow rate. However, all in vivo experiments (in vivo infusion study and initial uptake clearance in vivo) were done under the same conditions of anesthesia. As for hepatic blood flow rate, the dose-dependent effect of ONO-1301 can be discussed. Before beginning the ONO-1301 infusion, the hepatic blood flow rate was 59.1 ml/min/kg, similar to reported values (Nagata et al., 1990; Yokotaet al., 1976). After intravenous infusion of ONO-1301, the hepatic blood flow rates increased. The increase in hepatic blood flow rate at infusion rates of 0.2, 2 and 20 mg/kg/hr was 21%, 31% and 34%, respectively (table 2). Such an increase in hepatic blood flow rate may be one reason why CLtot did not decrease as much as EH. However, there may be another reason, because the decrease in CLtot at 2 mg/kg/hr compared with 0.2 mg/kg/hr was smaller than the corresponding decrease in hepatic clearance (CLH≈Qp · EH).

In general, CLH is expressed as a function ofQB, fB and CLint,all, where fBis the blood unbound fraction, and CLint,allrepresents the overall intrinsic clearance which includes not only metabolism and biliary excretion but also membrane permeability, as described by the following equation (Miyauchi et al., 1987;Pang and Gillette 1978):CLint,all=PS·CLint,met+CLint,bilePSeff+CLint,met+CLint,bile Equation 16where, PSinf and PSeffrepresent the membrane permeability clearance of unbound ligand for the influx and efflux processes, respectively, and CLint,metand CLint,bile represent the “exact” intrinsic clearances for metabolism and biliary excretion of the unbound ligand, respectively. From equation 16, possible explanations for the decrease in CLH as the infusion rate increases are: 1) saturation of hepatic uptake (PSinf ↓), 2) saturation of biliary excretion (CLint,bile ↓) and 3) saturation of metabolism (CLint,met ↓). After intravenous administration of [14C]ONO-1301 at various doses, the fraction of the metabolites to the total radioactivity in plasma and bile did not change with dose (H. Imawaka, unpublished data). Therefore, saturation of metabolism may not have occurred. To clarify the possibility that saturation of hepatic uptake and biliary excretion might occur, various pharmacokinetic parameters at steady state were analyzed. The biliary excretion clearance based on the plasma concentration of ONO-1301 (CLbile,plasma; 0.86 ml/min/kg) was much smaller than CLH (12.2 ml/min/kg) at 0.2 mg/kg/hr, which suggests that the biliary excretion did not contribute so much to the decrease in hepatic clearance of ONO-1301. Although CLbile,plasma decreased as the infusion rate increased, the clearances based on the liver concentration (CLbile,liver) increased. We, therefore, suggest that the decrease in CLH was not caused by saturation of biliary excretion. The increase in CLbile,liver with increasing infusion rate might be explained by saturation of the tissue binding of ONO-1301, because the hepatic concentration of ONO-1301 (150 μM) at 2 mg/kg/hr, was higher than the concentration of ligandin (50–100 μM) (Sathirakul et al., 1993; Arias et al., 1976), which was identified as the cytosolic binding protein of ONO-1301 by gel filtration (fig. 5). The finding that the binding capacity for the high-affinity binding is approximately 100 μM (fig. 4) also supports this idea.

In addition to these considerations, the decrease inKp as well as inEH with increasing infusion rate suggests that the nonlinear pharmacokinetics are caused by saturation of hepatic uptake. The Kp of this compound at the lowest infusion rate is large, 26, despite extensive plasma protein binding (98% binding, fig. 3). Such a highKp may be explained by two possible mechanisms; one is carrier-mediated active hepatic uptake as mentioned above, and/or more extensive binding to intracellular proteins than to plasma proteins. The binding to cytosolic proteins (ligandin as the major binding protein, fig. 5) was quantitated with 33% cytosol (fig.4). From the binding parameters (Kd,n(P)t) obtained, the binding of ONO-1301 to undiluted cytosol (100% cytosol) over the linear binding range was estimated from equation 7. The extrapolated percentage binding (97%) was close to the binding to plasma proteins (98%). Consequently, a high Kp value of 26 cannot be accounted for only by tissue binding, but carrier-mediated active uptake must also be considered.

To investigate directly the saturation of hepatic uptake, the time profiles of plasma and liver concentrations of ONO-1301 after intravenous administration at various doses (0.01–25 mg/kg) were analyzed in vivo. The early-phase hepatic uptake clearance (CLuptake,invivo) over the linear range (0.01–1 mg/kg) was approximately 29 ml/min/kg (fig. 7), which is close to the hepatic plasma flow rate (32.5 ml/min/kg, table 2). CLuptake,in vivodecreased as the dose increased and saturation of the uptake was observed (fig. 7). Such a nonlinearity in CLtotand the Kp value at steady state (table 1) could thus be attributed to saturation of hepatic uptake.

Furthermore, by use of isolated rat hepatocytes, the analysis of the kinetics in the Na+- dependent and -independent uptake provided one saturable component with aKm value of 15.6 μM (Na+-dependent) and 3.8 μM (Na+-independent), aVmax value of 5.9 nmol/min/mg (Na+-dependent) and 4.8 nmol/min/mg (Na+-independent) and nonspecific diffusion. From the kinetic parameters obtained, the uptake clearance (PSinflux,in vitro) in the presence of an external Na+ (corresponding to physiological conditions) was calculated to be 9400 ml/min/kg from equation 12. Furthermore, based on the in vitro parameters (fu, PSinflux,in vitro), CLuptake,in vivo was estimated from equations 13 to 15 to be 31.5 ml/min/kg, which is close to the hepatic plasma flow rate and agrees with the result of thein vivo study at a dose of 0.01 mg/kg (29 ml/min/kg, fig.6). Although the results from both in vitro and in vivo studies indicate that the hepatic uptake clearance is close to the hepatic plasma flow rate, the EHvalue at steady-state was 0.31 (much lower than 1). As understood easily from equation 16, this can be explained by the hypothesis that the PSeff value is much larger than the sum of the CLint,met and CLint,bile values.

We investigated the uptake mechanism of ONO-1301 with isolated rat hepatocytes. Both Na+-dependent and -independent uptake was observed. The uptake characteristics of ONO-1301, i.e., highly concentrative (equilibilium C/M ratio about 8000) (fig. 8), temperature dependent and sensitive to ATP depletors (table 3), demonstrate that the hepatic uptake of ONO-1301 is mediated by both a Na+-dependent and -independent carrier mediated active transport system. ONO-1301 is an organic anion with a carboxyl group and is an agonist specifically bound to PG receptors, hence, hepatic uptake processes may be mediated by the transporters (Ntcp, epoxide hydrolase, oatp or PGT) described in the introduction. To investigate which transporter is responsible for the hepatic uptake of ONO-1301, the mutual inhibition of hepatic uptake was examined. The uptake of ONO-1301 both in the presence and absence of external Na+ was inhibited by TCA and pravastatin (a typical non-bile acid organic anion) only partly. However, the half-inhibition concentrations of TCA and pravastatin for the inhibitable ONO-1301 uptake were 20 and 50 μM, and were comparable with the Km values for the uptake of TCA [Km = 15 (Na+-dependent), 57 (Na+-independent) μM, Anwer and Hegner, 1978] and pravastatin (Km = 29 μM, Yamazakiet al., 1993a) themselves, respectively (table 3). ONO-1301 also inhibited the uptake of TCA and pravastatin almost completely, and the half-inhibition concentration of ONO-1301 was approximately 10 μM (table 3), which agreed well with the Kmvalues (4–7 μM) of ONO-1301 uptake (fig. 9). These mutual inhibition studies suggest that the hepatic uptake of ONO-1301 may be mediated at least partly by Na+-dependent TCA transporters and Na+-independent oatp. In addition, we cannot exclude the possibility of a contribution from PGT.

To clarify the quantitative contribution of Ntcp, epoxide hydrolase, oatp and PGT to ONO-1301 uptake by hepatocytes, detailed kinetic studies involving the analysis of the mutual inhibition pattern in isolated rat hepatocytes and the mammalian cells to which these transporters are transfected are necessary and are currently underway in our laboratory.

Acknowledgments

We would like to thank ONO Pharmaceutical Company Co., LTD., for providing labeled and unlabeled ONO-1301. We also thank Sankyo Co., LTD., for providing labeled and unlabeled pravastatin.

Footnotes

  • Send reprint requests to: Yuichi Sugiyama, Ph.D., Professor and Chair, Faculty of Pharmaceutical Sciences, University of Tokyo, 7–3-1, Hongo, Bunkyo-ku, Tokyo 113, Japan.

  • Abbreviations:
    ONO-1301
    7,8-dihydro-5-[(E)-[[a-(3-pyridyl)benzylidene]aminooxy]ethyl]-1-naphthyloxy]acetic acid
    PG
    prostaglandin
    TCA
    taurocholate
    DBSP
    dibromosulfophthalein
    FCCP
    carbonylcyanide-p-(trifluoromethoxy)-phenylhydrazone
    Ntcp
    Na+-taurocholate cotransporting polypeptide
    oatp
    Na+-independent organic anion transporting polypeptide
    PGT
    prostaglandin transporter
    P-gp
    P-glycoprotein
    SD rats
    Sprague-Dawley rats
    Km
    Michaelis constant
    Vmax
    maximum transport velocity
    Pdif
    nonspecific diffusion clearance
    CLtot
    total body clearance
    EH
    hepatic extraction ratio
    CLH
    hepatic clearance
    QB
    hepatic blood flow rate
    Qp
    hepatic plasma flow rate
    Ht
    hematocrit
    Kp value
    liver-to-plasma concentration ratio
    CLbile,plasma and CLbile,liver
    biliary excretion clearances based on plasma and liver concentrations
    n(P)t
    binding capacity
    Kd
    dissociation constant
    CLuptake,in vivo
    hepatic uptake clearance in vivo
    AUC(0-t)
    the area under the plasma concentration-time curve from time 0 to t
    PSinflux,in vitro
    permeability-surface area product obtained in vitro
    HPLC
    high-performance liquid chromatography
    GST
    glutatione S-transferase
    EGTA
    ethylene glycol bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid
    HEPES
    N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid
    • Received November 1, 1996.
    • Accepted November 13, 1997.

References

  1. ↵
    1. Anwer MS,
    2. Hegner D
    (1978) Effect of Na+ on bile acid uptake by isolated rat hepatocytes. Hoppe-Seyler’s Z Physiol Chem 359:181–192.
    OpenUrlPubMed
  2. ↵
    1. Arias IM,
    2. Jakoby WB
    1. Arias IM,
    2. Fleischner G,
    3. Kirsch R,
    4. Mishkin S,
    5. Gatmaitan Z
    (1976) On the structure, regulation, and function of ligandin. in Glutathione: Metabolism and Function, eds Arias IM, Jakoby WB (Raven Press, New York), p 175.
  3. ↵
    1. Baur H,
    2. Kasperek S,
    3. Pfaff E
    (1975) Criteria of viability of isolated liver cells. Heppe-Seyler’s Z. Physiol Chem 356:827–838.
  4. ↵
    1. Chung YB,
    2. Miyauchi S,
    3. Sugiyama Y,
    4. Harashima H,
    5. Iga T,
    6. Hanano M
    (1990) Effect of various organic anions on the plasma disappearance of 1-anilino-8-naphthalene sulfonate (ANS). J Hepatol 11:240–251.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Elferink RPJO,
    2. Meijer DKF,
    3. Kuipers F,
    4. Jansen PLM,
    5. Groan AK,
    6. Groothis GMM
    (1995) Hepatobiliary secretion of organic compounds: Molecular mechanisms of membrane transport. Biochim Biophys Acta 1241:215–268.
    OpenUrlPubMed
  6. ↵
    1. Hagenbuch B,
    2. Stieger B,
    3. Foguet M,
    4. Lübbert H,
    5. Meier PJ
    (1991) Functional expression cloning and characterization of the hepatocytes Na+/bile acid cotransport system. Proc Natl Acad Sci USA 88:10629–10633.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Hagenbuch B,
    2. Meier PJ
    (1994) Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest 93:1326–1331.
  8. ↵
    1. Inoue M,
    2. Kinne R,
    3. Tran T,
    4. Arias IM
    (1982) Taurocholate transport by rat liver sinusoidal membrane vesicles: Evidence of sodium co-transport. Hepatology 2:572–579.
    OpenUrlPubMed
  9. ↵
    1. Ishikawa T,
    2. Muller M,
    3. Klunemann C,
    4. Schaub T,
    5. Keppler D
    (1990) ATP-dependent primary active transport of cystenyl leukotrienes across liver canalicular membrane: Role of ATP-dependent transport system for glutatione S-conjugates. J Biol Chem 265:19279–19286.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Ito K,
    2. Suzuki H,
    3. Hirohashi T,
    4. Kume K,
    5. Shimizu T,
    6. Sugiyama Y
    (1996) Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. Am J Physiol 272:G16–G22.
    OpenUrl
  11. ↵
    1. Iwatsubo T,
    2. Hirota N,
    3. Ooie T,
    4. Suzuki H,
    5. Sugiyama Y
    (1996) Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm Drug Dispos 17:273–310.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Jacquemin E,
    2. Hagenbuch B,
    3. Stieger B,
    4. Wolkoff AW,
    5. Meier PJ
    (1991) Expression of the hepatocellular chloride-dependent sulfobromophthalein uptake system in Xenopus laevis oocytes. J Clin Invest 88:2146–2149.
  13. ↵
    1. Jacqemin E,
    2. Hagenbuch B,
    3. Stieger B,
    4. Wolkoff AW,
    5. Meier PJ
    (1994) Expression cloning of a rat liver Na+/-independent organic anion transporter. Proc Natl Acad Sci USA 91:133–137.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Kanai N,
    2. Lu R,
    3. Satriano JA,
    4. Bao Y,
    5. Wolkoff AW,
    6. Schuster VL
    (1995) Identification and characterization of a prostaglandin transporter. Science 268:866–869.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Kim DC,
    2. Sugiyama Y,
    3. Satoh H,
    4. Fuwa T,
    5. Iga T,
    6. Hanano M
    (1988) Kinetic analysis of in vivo receptor-dependent binding of human epidermal growth factor by rat tissues. J Pharm Sci 77:200–207.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Kobayashi K,
    2. Sogame Y,
    3. Hara H,
    4. Hayashi K
    (1990) Mechanism of glutathione S-conjugate transport in canalicular and basolateral rat liver plasma membrane vesicles. J Biol Chem 265:7737–7741.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Samuelsson B,
    2. Ramwell PW,
    3. Paoletti R,
    4. Folco G,
    5. Granström E,
    6. Nicosia S
    1. Kondo K,
    2. Machii K,
    3. Narita M,
    4. Kawamoto A,
    5. Yamasaki S,
    6. Hamanaka N
    (1995) ONO-AP-500–02: A non prostanoid prostaglandin I2 mimetic with inhibitory activity against thromboxane synthase. in Advances in Prostaglandin, Thromboxane, and Leukotriene Research, eds Samuelsson B, Ramwell PW, Paoletti R, Folco G, Granström E, Nicosia S (Raven Press, Ltd. New York), 23:401–403.
  18. ↵
    1. Kullak-Ublick GA,
    2. Hagenbuch B,
    3. Stieger B,
    4. Schtengart CD,
    5. Hofmann AF,
    6. Wolkoff AW,
    7. Meier PJ
    (1995) Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 109:1274–1282.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Lin JH,
    2. Sugiyama Y,
    3. Awazu S,
    4. Hanano M
    (1980) Kinetic studies on the deethylation of ethoxybenzamide: A comparative study with isolated hepatocytes and liver microsomes of rats. Biochem Pharmacol 29:2826–2830.
    OpenUrl
  20. ↵
    1. Meijer DKF,
    2. Mol WEM,
    3. Muller M,
    4. Kurz G
    (1990) Carrier-mediated transport in the hepatic distribution and elimination of drugs, with special reference to the category of organic cations. J Pharmacokinet Biopharm 18:35–70.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Mayer R,
    2. Kartenbeck J,
    3. Büchler M,
    4. Jedlitschky G,
    5. Leier I,
    6. Keppler D
    (1995) Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes. J Cell Biol 131:137–150.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Miyauchi S,
    2. Sugiyama Y,
    3. Sawada Y,
    4. Iga T,
    5. Hanano M
    (1987) Kinetics of hepatic transport of 4-methylumbelliferone in rats: Analysis by multiple indicator dilution method. J Pharmacokinet Biopharm 15:25–38.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Miyauchi S,
    2. Sawada Y,
    3. Iga T,
    4. Hanano M,
    5. Sugiyama Y
    (1993) Comparison of the hepatic clearance of fifteen drugs with a wide range of membrane permeabilities determined using isolated rat hepatocytes and perfused rat livers. Pharmacol Res 10:434–440.
  24. ↵
    1. Nagata O,
    2. Murata M,
    3. Kato H,
    4. Terasaki T,
    5. Sato H,
    6. Tsuji A
    (1990) Physiological pharmacokinetics of a new muscle-relaxant, inaperisone, combined with its pharmacological effect on blood flow rate. Drug Metab Dispos 18:902–910.
    OpenUrlAbstract
  25. ↵
    1. Pang KS,
    2. Gillette R
    (1978) Kinetics of metabolite formation and elimination in the perfused rat liver preparation: Difference between the elimination of preformed acetaminophen and acetaminophen formed from phenacetin. J Pharmacol Exp Ther 207:178–194.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Petzinger E
    (1994) Transport of organic anions in the liver. An update on bile acid, fatty acid, monocarboxylate, anionic amino acid, cholephilic organic anion, and anionic drug transport. Rev Physiol Biochem Pharmacol 123:47–211.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Roberts MS,
    2. Rowland M
    (1986) A dispersion model of hepatic elimination. 2. Steady state considerations. Influence of blood flow, protein binding and hepatocellular enzymatic activity. J Pharmacokinet Biopharm 14:261–288.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Sathirakul K,
    2. Suzuki H,
    3. Yasuda K,
    4. Hanano M,
    5. Tagaya O,
    6. Horie T,
    7. Sugiyama Y
    (1993) Kinetic analysis of hepatobiliary transport of organic anions in eisai hyperbilirubinemic mutant rats. J Pharmacol Exp Ther 265:1301–1312.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Schwenk M
    (1980) Transport systems of isolated hepatocytes. Studies on the transport of biliary compounds. Arch Toxicol 44:113–126.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Sugita O,
    2. Sawada Y,
    3. Sugiyama Y,
    4. Iga T,
    5. Hanano M
    (1982) Physiologically based pharmacokinetics of drug-drug interaction: A study of tolubutamide-sulfonamide interaction in rats. J Pharmacokinet Biopharm 10:297–316.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Sugiyama Y,
    2. Yamada T,
    3. Kaplowitz N
    (1981) Glutathione S-transferase in elasmobranch liver: Molecular heterogeneity, catalytic and binding properties and purification. Biochem J 199:749–756.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Sugiyama Y,
    2. Yamada T,
    3. Kaplowitz N
    (1983) Newly identified bile acid binders in rat liver cytosol: Purification and comparison with glutathione S-transferases. J Biol Chem 258:3602–3607.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Tsao SC,
    2. Sugiyama Y,
    3. Shinmura K,
    4. Sawada Y,
    5. Nagase S,
    6. Iga T,
    7. Hanano M
    (1988) Protein mediated uptake of rose bengal in an albuminemic rats (NAR); Albumin is not indispensable to the protein mediated transport of rose bengal. Drug Metab Dispos 16:482–489.
    OpenUrlAbstract
  34. ↵
    1. Takenaka O,
    2. Horie T,
    3. Suzuki H,
    4. Kobayashi K,
    5. Sugiyama Y
    (1995) Kinetic analysis of hepatobiliary transport for conjugative metabolites in the perfused liver of mutant rats (EHBR) with hereditary conjugative hyperbilirubinemia. Pharmacol Res 12:1746–1755.
  35. ↵
    1. von Dippe P,
    2. Amoui M,
    3. Stellwagen RH,
    4. Levy D
    (1996) The functional expression of sodium-dependent bile acid transport in Madin-Darby canine kidney cells transfected with the cDNA for microsomal epoxide hydrolase. J Biol Chem 271:18176–18180.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Watkins JB,
    2. Klaassen CD
    (1983) Chemically-induced alteration of UDP-glucuronic acid concentration in rat liver. Drug Metab Dispos 11:37–40.
    OpenUrlAbstract
  37. ↵
    1. Yamaoka K,
    2. Tanigawara Y,
    3. Nakagawa Y,
    4. Uno T
    (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobiodyn 4:879–885.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Yamazaki M,
    2. Suzuki H,
    3. Hanano M,
    4. Tokui T,
    5. Komai T,
    6. Sugiyama Y
    (1993a) Na+-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 264:G36–G44.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Yamazaki M,
    2. Suzuki H,
    3. Hanano M,
    4. Sugiyama Y
    (1993b) Different relationships between cellular ATP and hepatic uptake among taurocholate, cholate, and organic anions. Am J Physiol 264:G693–G701.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. Yamazaki M,
    2. Suzuki H,
    3. Sugiyama Y
    (1996) Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics: Pharmacol Res 13:497–513.
  41. ↵
    1. Yanai M,
    2. Sugiyama Y,
    3. Iga T,
    4. Fuwa T,
    5. Hanano M
    (1990) Kinetic analysis of the downregulation of epidermal growth factor receptors in rats in vivo. Am J Physiol 258:C593–C598.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Yokota M,
    2. Iga T,
    3. Awazu S,
    4. Hanano M
    (1976) Simple method of hepatic venous blood sampling in the rat. J Appl Physiol 4:349–441.
    OpenUrl
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools
OtherDRUG METABOLISM AND DISPOSITION

Kinetic Study of the Hepatobiliary Transport of a New Prostaglandin Receptor Agonist

Haruo Imawaka and Yuichi Sugiyama
Journal of Pharmacology and Experimental Therapeutics March 1, 1998, 284 (3) 949-957;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section